Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

In recent years, lutetium-177 (177Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we report on an early experience of177Lu-PSMA therapy with an evaluation o...

Full description

Bibliographic Details
Main Authors: Majid Assadi, Samira Rezaei, Esmail Jafari, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Farshad Zohrabi, AbdulLatif Amini, Saeid Keshmiri, Habibollah Dadgar, Hojjat Ahmadzadehfar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:World Journal of Nuclear Medicine
Subjects:
biochemical response
lutetium-177 -prostate-specific membrane antigen
prostate cancer
radioligand therapy
toxicity
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=1;spage=15;epage=20;aulast=Assadi

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=1;spage=15;epage=20;aulast=Assadi

Similar Items